drugset / Trial / NCT07287189
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.
Timeline
- Start
- 2025-12-08
- Primary completion
- 2027-03-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SAT-3247 | Small molecule | 60 mg | Oral |
| Comparator | SAT-3247 | Small molecule | 120 mg | Oral |